Emilio Casanova
YOU?
Author Swipe
View article: Quantitative Proteomics Identifies Potential Molecular Adaptations in Mouse Models of Congenital Stationary Night Blindness Type 2
Quantitative Proteomics Identifies Potential Molecular Adaptations in Mouse Models of Congenital Stationary Night Blindness Type 2 Open
Pathogenic variants in the CACNA1F gene are linked to congenital stationary night blindness type 2 though their specific molecular effects remain elusive. This study examines the retinal impact of two variants: a truncation (RX) and a gain…
View article: Multisite hernia treatment: the robotic approach makes it feasible
Multisite hernia treatment: the robotic approach makes it feasible Open
Background The use of robotic surgery for combined abdominal wall hernias, including multiquadrant hernias, is underexplored in the literature. While the prevalence of simultaneous hernias is not well documented, they represent a frequent …
View article: TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis
TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis Open
Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine co…
View article: Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma
Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma Open
Inflammation is a widely recognized key contributor to KRAS-driven lung adenocarcinoma (LUAD). Tumor-associated macrophages (TAM) are an integral part of the tumor microenvironment and create a supportive niche that sustains inflammation-d…
View article: Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia
Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia Open
Acute myeloid leukemia (AML) is the most common acute leukemia and is predominantly affecting the elderly. It is a heterogenous disease, showing a broad spectrum of genomic alterations and mutations that influence the clinical outcome and …
View article: RadioFlow Cytometry Reveals That [<sup>18</sup>F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level
RadioFlow Cytometry Reveals That [<sup>18</sup>F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level Open
Tumor metabolism is a hallmark of cancer, yet cellular heterogeneity within the tumor microenvironment presents a significant challenge, as bulk analysis masks the diverse metabolic profiles of individual cell populations. This complexity …
View article: <i>SF3B1</i> Mutation Significance in Myeloid Neoplasms without Anemia
<i>SF3B1</i> Mutation Significance in Myeloid Neoplasms without Anemia Open
Introduction. The proposed classifications (WHO2022/ICC) define Myelodysplastic Neoplasms/Syndromes with SF3B1 mutation (MDS-SF3B1) and myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T) b…
View article: Multiplex genome editing eliminates the Warburg Effect without impacting growth rate in mammalian cells
Multiplex genome editing eliminates the Warburg Effect without impacting growth rate in mammalian cells Open
The Warburg effect is ubiquitous in proliferative mammalian cells, including cancer cells, but poses challenges for biopharmaceutical production, as lactate accumulation inhibits cell growth and protein production. Previous efforts to elim…
View article: STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance
STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance Open
Acute myeloid leukemia (AML) is a heterogenous disease characterized by the clonal expansion of myeloid progenitor cells. Despite recent advancements in the treatment of AML, relapse still remains a significant challenge, necessitating the…
View article: P09.05 Novel A20 based therapeutic strategies to fight lung cancer
P09.05 Novel A20 based therapeutic strategies to fight lung cancer Open
Background Lung cancer still accounts for the most cancer-related deaths worldwide. Although immune checkpoint blockade therapy is now the frontline therapy for lung adenocarcinomas with non-targetable oncogenic KRAS mutations, patients st…
View article: High-throughput ligand profile characterization in novel biosensor cell lines expressing seven heterologous olfactory receptors for the detection of volatile plant biomarkers
High-throughput ligand profile characterization in novel biosensor cell lines expressing seven heterologous olfactory receptors for the detection of volatile plant biomarkers Open
Agriculturally important crop plants emit a multitude of volatile organic compounds (VOCs), which are excellent indicators of their health status and/or their interaction with pathogens and pests. Here, we present the generation of a novel…
View article: Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Targeted Protein Degradation: Clinical Advances in the Field of Oncology Open
The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into th…
View article: Tyk2 is a tumor suppressor in colorectal cancer
Tyk2 is a tumor suppressor in colorectal cancer Open
Janus kinase Tyk2 is implicated in cancer immune surveillance, but its role in solid tumors is not well defined. We used Tyk2 knockout mice (Tyk2Δ/Δ) and mice with conditional deletion of Tyk2 in hematopoietic (Tyk2ΔHem) or intestinal epit…
View article: Down-regulation of A20 promotes immune escape of lung adenocarcinomas
Down-regulation of A20 promotes immune escape of lung adenocarcinomas Open
A20 represents an immune checkpoint in lung adenocarcinomas, and its loss may be compensated by targeting the TBK1–STAT1–PD-L1 axis.
View article: Efficient production of recombinant secretory IgA against Clostridium difficile toxins in CHO-K1 cells
Efficient production of recombinant secretory IgA against Clostridium difficile toxins in CHO-K1 cells Open
Despite the essential role secretory IgAs play in the defense against pathogenic invasion and the proposed value of recombinant secretory IgAs as novel therapeutics, currently there are no IgA-based therapies in clinics. Secretory IgAs are…
View article: Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future Open
Lung cancer is the most frequent cancer with an aggressive clinical course and high mortality rates. Most cases are diagnosed at advanced stages when treatment options are limited and the efficacy of chemotherapy is poor. The disease has a…
View article: STAT3: Versatile Functions in Non-Small Cell Lung Cancer
STAT3: Versatile Functions in Non-Small Cell Lung Cancer Open
Signal Transducer and Activator of Transcription 3 (STAT3) activation is frequently found in non-small cell lung cancer (NSCLC) patient samples/cell lines and STAT3 inhibition in NSCLC cell lines markedly impairs their survival. STAT3 also…
View article: Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma Open
EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFRT790M and EGFRC797S. It is generally assumed that these secondary mut…
View article: A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions
A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions Open
Genetically-engineered mouse models (GEMMs) lacking diseased-associated gene(s) globally or in a tissue-specific manner represent an attractive tool with which to assess the efficacy and toxicity of targeted pharmacological inhibitors. Sta…
View article: JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression Open
Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐coo…
View article: Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis
Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis Open
Endostatin, the C-terminal fragment of type XVIII collagen, was shown to be one of the most potent endothelial cell-specific inhibitors of angiogenesis. As altered circulating endostatin concentration is associated with impaired kidney fun…
View article: STAT3β is a tumor suppressor in acute myeloid leukemia
STAT3β is a tumor suppressor in acute myeloid leukemia Open
Signal transducer and activator of transcription 3 (STAT3) exists in 2 alternatively spliced isoforms, STAT3α and STAT3β. Although truncated STAT3β was originally postulated to act as a dominant-negative form of STAT3α, it has been shown t…